Galleri Multi-Cancer Signal

Most of the cancers that kill people have no routine screening test. Pancreas, ovary, stomach, liver, kidney, esophagus: you can have one of these growing for years with a clean bill of health from your annual physical. Galleri was built to change that math.

It is a single blood draw that looks for chemical fingerprints of tumor DNA circulating in your bloodstream, screens for signals from more than 50 cancers, and, when it finds one, predicts where in your body the cancer is most likely coming from.

What the Test Actually Looks For

Galleri is an MCED (multi-cancer early detection) test. It does not measure a hormone, an enzyme, or a tumor marker like PSA or CA-125. Instead, it analyzes patterns of DNA methylation, which are small chemical tags on DNA that act like on/off switches for genes, in fragments of cell-free DNA floating in your blood. Cancer cells leave behind DNA with a distinctive methylation pattern, and a machine-learning model trained on thousands of samples is used to recognize that pattern.

The result is not a number on a scale. It comes back as either cancer signal detected or no cancer signal detected. When a signal is detected, the report also names the one or two most likely tissues of origin (called the cancer signal origin, or CSO).

How Accurate the Test Is

Galleri is built to be highly specific, meaning it rarely flags cancer in people who do not have it. In a clinical validation study of 4,077 people, specificity was 99.5%. Overall sensitivity, meaning the share of true cancers it catches, was 51.5%. Detection improves dramatically as cancer advances: 16.8% at stage I, 40.4% at stage II, 77.0% at stage III, and 90.1% at stage IV. For the 12 cancers responsible for about two-thirds of US cancer deaths, sensitivity at stages I to III was 67.6%.

When the test does flag a signal, it correctly predicts the tissue of origin in about 88.7% of cases, which is unusual for a blood test and clinically valuable, because it tells your doctor where to start looking.

Source: Matrana et al. 2025; Schrag et al. 2023 (PATHFINDER); Ghosh et al. 2026 (Mayo enterprise-wide implementation); Nicholson et al. 2023 (SYMPLIFY); Klein et al. 2021 (validation).

Cancers Without Standard Screening

This is where Galleri does something no other available test does. Standard screening covers a handful of cancers: breast, colorectal, cervical, lung in current or former heavy smokers, and prostate (via PSA, framed as shared decision-making by the USPSTF and more broadly recommended by the AUA). That leaves most cancer types invisible to routine medicine until symptoms appear, which is usually late. Case series and large cohort data show Galleri picking up early-stage cancers of the ovary, kidney, pancreas, and head and neck in people who had no symptoms and no other reason to test.

Modeling work in England projected that adding an MCED test to standard screening for adults aged 50 to 79 could meaningfully reduce late-stage diagnoses and cancer deaths, though those numbers come from assumptions and not yet from completed trials.

What a Positive Result Actually Means

A cancer signal detected result is not a cancer diagnosis. In the real-world data on more than 100,000 tests, the positive predictive value in the asymptomatic subset was about 49%, meaning roughly half of people with a positive result were ultimately diagnosed with cancer. In PATHFINDER, 38% of positives had a confirmed cancer. The other half to two-thirds had no cancer found after workup, though some may have had occult disease that was not yet detectable by imaging.

In PATHFINDER, the median time from a positive result to a diagnostic resolution was 79 days overall, and 162 days for the false positives. That is months of additional imaging, possibly biopsies, and the psychological weight of waiting. Qualitative interviews with people who received a cancer signal showed real distress, particularly when results came without a clear plan for follow-up.

It is also worth understanding what stage the detected cancers tend to be. Despite the early-detection framing, MCED-detected cancers in real-world use have skewed toward advanced stages. In PATHFINDER, only 48% of detected cancers were stage I or II, compared with 73% of cancers found through usual care. In the large real-world series, just 28% were stage I or II, while 48% were stage IV.

What a Negative Result Does Not Mean

A no cancer signal detected result does not mean you are cancer-free. The test misses most stage I cancers and a meaningful share of stage II. Some cancers shed little DNA into the blood and are essentially invisible to this kind of testing. A negative Galleri should reduce, but not eliminate, your concern about undetected cancer, and it does not replace mammograms, colonoscopies, cervical screening, or low-dose CT in eligible smokers. Treat it as one valuable input alongside your other screening, not as a clean bill of health.

Why Tracking Matters More Than a Single Test

Galleri is designed as an annual screening test, not a one-time check. A single negative result tells you nothing about whether a cancer will emerge in the next year. The point of repeated testing is to catch cancers in the window when they are still curable, before symptoms appear. Modeling work compared annual and every-other-year testing in adults aged 50 to 79 and found annual screening produced more reduction in late-stage diagnoses and deaths over five years. No guideline or professional society currently endorses annual MCED screening; this approach reflects the test's intended use and modeling work, not consensus recommendations.

A reasonable approach for a proactive adult: get a baseline test in your fifties (earlier if you have strong family history of cancer), then repeat annually. Continue your standard age-appropriate screening on its normal schedule. If you ever get a cancer signal detected result, the next step is not to retest, but to investigate.

What to Do If You Get a Cancer Signal

The report will name a predicted cancer signal origin, usually one or two organs. The workup follows that lead. If the predicted origin is the colon, that means colonoscopy. If it points to the ovaries or pelvis, pelvic ultrasound or MRI. If it points to the lungs, a chest CT. Whole-body imaging is sometimes used when the origin is uncertain, but targeted imaging guided by the predicted origin is generally more efficient and led to diagnostic resolution in the majority of PATHFINDER cases.

You will want a clinician who can coordinate this workup quickly. An oncologist, a primary care doctor familiar with MCED testing, or a specialist matched to the predicted origin (gastroenterologist, gynecologist, pulmonologist) is the right starting point. If the targeted workup is clean, your doctor may recommend a short interval of additional imaging or surveillance, because the test can occasionally pick up cancers that imaging cannot yet see. Do not assume a negative workup means the positive Galleri was wrong; document the result and stay alert to symptoms.

What This Test Is Not

Galleri is not a replacement for any existing cancer screening. It does not measure inflammation, tumor markers, or genetic risk. It is also not the same as germline genetic testing for inherited cancer syndromes like BRCA mutations. Those tests tell you whether you carry a variant that raises your lifetime risk; Galleri tells you whether your body is showing signs of cancer right now.

The test is not yet FDA-approved, though FDA review is ongoing. It is commercially available as a laboratory-developed test and is not included in formal screening guidelines. To date, no study has demonstrated that Galleri reduces cancer mortality. The NHS-Galleri randomized trial of about 140,000 adults, the only randomized controlled trial of the test, reported results in 2026 and did not meet its primary endpoint of reducing the combined incidence of stage III and stage IV cancers. GRAIL highlighted a reduction in stage IV diagnoses considered separately, but independent experts have said the findings fall short of demonstrating sufficient clinical benefit to warrant population-wide implementation, and the NHS had previously declined to expand the trial after reviewing first-year interim results.

When Results Can Be Misleading

Two situations are most likely to distort what a single Galleri result means for you:

• Early-stage cancer: sensitivity at stage I is only about 17%, so a negative result has real limits in ruling out very early disease.
• Cancers that shed little DNA: some tumor types release very little cell-free DNA into the blood, particularly when small or indolent, and may not generate a detectable signal regardless of stage.
• Recent acute illness or surgery: the test is designed for stable, asymptomatic adults; how acute events affect a single reading has not been formally studied, but it is reasonable to defer testing until you have recovered from any recent illness or procedure.
• Active cancer treatment: Galleri is not designed for use in people with a known active cancer; it is a screening tool, not a monitoring tool.

Current research does not show that common medications, like statins, metformin, GLP-1 agonists, PPIs, thyroid drugs, or steroids, distort Galleri results in any documented way. Performance has been similar across age, sex, and racial and ethnic groups in the populations studied so far.